Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6111703 | 0.81 | AKR1C3 (0.55) | AKR1C3AKR1C2GRM5NPC1 | |
| SCHEMBL3956772 | 0.79 | MAOA (0.52) | MAOAMAOBRAB9AGSK3BRXRA | |
| SCHEMBL12578150 | 0.79 | MAOB (0.50) | MAOAMAOBRAB9AFFAR1GRM5 | |
| SCHEMBL6187222 | 0.78 | RAB9A (0.62) | GSTP1MAOAMAOBRAB9AFFAR1 | |
| SCHEMBL29558755 | 0.78 | RXRA (0.63) | MAOAMAOBARBACE1RXRA | |
| SCHEMBL158270 | 0.77 | RAB9A (0.68) | MAOAMAOBRAB9ALCKBACE1 | |
| SCHEMBL865349 | 0.75 | RAB9A (0.71) | MAOAMAOBRAB9AFFAR1FFAR4 | |
| SCHEMBL8083057 | 0.75 | MAOB (0.55) | GSTP1MAOAMAOBRAB9ATOP1 | |
| SCHEMBL2807881 | 0.75 | MAOA (0.70) | GSTP1MAOAMAOBRAB9AFFAR1 | |
| SCHEMBL3163377 | 0.74 | RAB9A (0.46) | GSTP1MAOAMAOBRAB9AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877607-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-6563008-B2 | Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast | AVENTIS PHARMA S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| US-6288126-B1 | Biphenyl compounds and use thereof as oestrogenic agents | AVENTIS PHARMA S.A. | 2001-09-11 | — | — | US | disclosed |
| EP-0757982-B1 | Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL INC (FR) | 2000-09-20 | — | — | EP | disclosed |
| US-5965763-A | Biphenyl compounds | HOECHST MARION ROUSSEL (FR) | 1999-10-12 | — | — | US | disclosed |
| EP-0877607-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1998-11-18 | — | — | EP | disclosed |
| US-5827887-A | 5-ALPHA REDUCTASE INHIBITORS | ROUSSEL UCLAF (FR) | 1998-10-27 | — | — | US | disclosed |
| WO-1997027846-A1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | HOECHST MARION ROUSSEL (FR) | 1997-08-07 | — | — | WO | disclosed |
| EP-0757982-A1 | Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1997-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | GSTP1 564/4885MAOA 1209/4885MAOB 507/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | GSTP1 389/4885MAOA 433/4885MAOB 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.